Form 8-K - Current report:
SEC Accession No. 0001437749-24-031362
Filing Date
2024-10-16
Accepted
2024-10-16 16:27:16
Documents
14
Period of Report
2024-10-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 FORM 8-K nby20241015_8k.htm   iXBRL 8-K 33973
  Complete submission text file 0001437749-24-031362.txt   172400

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nby-20241016.xsd EX-101.SCH 3402
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nby-20241016_def.xml EX-101.DEF 11805
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nby-20241016_lab.xml EX-101.LAB 15859
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nby-20241016_pre.xml EX-101.PRE 12020
16 EXTRACTED XBRL INSTANCE DOCUMENT nby20241015_8k_htm.xml XML 2977
Mailing Address 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608
Business Address 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608 (510) 899-8800
NovaBay Pharmaceuticals, Inc. (Filer) CIK: 0001389545 (see all company filings)

EIN.: 680454536 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33678 | Film No.: 241374943
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)